Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.
Highlights
The global Metabolic Syndrome market was valued at US$ 25920 million in 2022 and is anticipated to reach US$ 34940 million by 2029, witnessing a CAGR of 5.1% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Metabolic Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Syndrome.
The Metabolic Syndrome market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Metabolic Syndrome market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolic Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma
Segment by Type
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Syndrome Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Diabetes
1.2.3 Obesity
1.2.4 Hypercholesterolemia
1.2.5 Lysosomal storage diseases
1.3 Market by Application
1.3.1 Global Metabolic Syndrome Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Syndrome Market Perspective (2018-2029)
2.2 Metabolic Syndrome Growth Trends by Region
2.2.1 Global Metabolic Syndrome Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Metabolic Syndrome Historic Market Size by Region (2018-2023)
2.2.3 Metabolic Syndrome Forecasted Market Size by Region (2024-2029)
2.3 Metabolic Syndrome Market Dynamics
2.3.1 Metabolic Syndrome Industry Trends
2.3.2 Metabolic Syndrome Market Drivers
2.3.3 Metabolic Syndrome Market Challenges
2.3.4 Metabolic Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Syndrome Players by Revenue
3.1.1 Global Top Metabolic Syndrome Players by Revenue (2018-2023)
3.1.2 Global Metabolic Syndrome Revenue Market Share by Players (2018-2023)
3.2 Global Metabolic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Syndrome Revenue
3.4 Global Metabolic Syndrome Market Concentration Ratio
3.4.1 Global Metabolic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Syndrome Revenue in 2022
3.5 Metabolic Syndrome Key Players Head office and Area Served
3.6 Key Players Metabolic Syndrome Product Solution and Service
3.7 Date of Enter into Metabolic Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Syndrome Breakdown Data by Type
4.1 Global Metabolic Syndrome Historic Market Size by Type (2018-2023)
4.2 Global Metabolic Syndrome Forecasted Market Size by Type (2024-2029)
5 Metabolic Syndrome Breakdown Data by Application
5.1 Global Metabolic Syndrome Historic Market Size by Application (2018-2023)
5.2 Global Metabolic Syndrome Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Metabolic Syndrome Market Size (2018-2029)
6.2 North America Metabolic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Metabolic Syndrome Market Size by Country (2018-2023)
6.4 North America Metabolic Syndrome Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metabolic Syndrome Market Size (2018-2029)
7.2 Europe Metabolic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Metabolic Syndrome Market Size by Country (2018-2023)
7.4 Europe Metabolic Syndrome Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Syndrome Market Size (2018-2029)
8.2 Asia-Pacific Metabolic Syndrome Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Metabolic Syndrome Market Size by Region (2018-2023)
8.4 Asia-Pacific Metabolic Syndrome Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metabolic Syndrome Market Size (2018-2029)
9.2 Latin America Metabolic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Metabolic Syndrome Market Size by Country (2018-2023)
9.4 Latin America Metabolic Syndrome Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Syndrome Market Size (2018-2029)
10.2 Middle East & Africa Metabolic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Metabolic Syndrome Market Size by Country (2018-2023)
10.4 Middle East & Africa Metabolic Syndrome Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Detail
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Metabolic Syndrome Introduction
11.1.4 Novo Nordisk Revenue in Metabolic Syndrome Business (2018-2023)
11.1.5 Novo Nordisk Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Metabolic Syndrome Introduction
11.2.4 Sanofi Revenue in Metabolic Syndrome Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Metabolic Syndrome Introduction
11.3.4 Merck Revenue in Metabolic Syndrome Business (2018-2023)
11.3.5 Merck Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Metabolic Syndrome Introduction
11.4.4 AstraZeneca Revenue in Metabolic Syndrome Business (2018-2023)
11.4.5 AstraZeneca Recent Development
11.5 Eli Lily
11.5.1 Eli Lily Company Detail
11.5.2 Eli Lily Business Overview
11.5.3 Eli Lily Metabolic Syndrome Introduction
11.5.4 Eli Lily Revenue in Metabolic Syndrome Business (2018-2023)
11.5.5 Eli Lily Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Metabolic Syndrome Introduction
11.6.4 AbbVie Revenue in Metabolic Syndrome Business (2018-2023)
11.6.5 AbbVie Recent Development
11.7 Actelion Pharmaceuticals
11.7.1 Actelion Pharmaceuticals Company Detail
11.7.2 Actelion Pharmaceuticals Business Overview
11.7.3 Actelion Pharmaceuticals Metabolic Syndrome Introduction
11.7.4 Actelion Pharmaceuticals Revenue in Metabolic Syndrome Business (2018-2023)
11.7.5 Actelion Pharmaceuticals Recent Development
11.8 Adocia
11.8.1 Adocia Company Detail
11.8.2 Adocia Business Overview
11.8.3 Adocia Metabolic Syndrome Introduction
11.8.4 Adocia Revenue in Metabolic Syndrome Business (2018-2023)
11.8.5 Adocia Recent Development
11.9 Aegerion Pharmaceuticals
11.9.1 Aegerion Pharmaceuticals Company Detail
11.9.2 Aegerion Pharmaceuticals Business Overview
11.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Introduction
11.9.4 Aegerion Pharmaceuticals Revenue in Metabolic Syndrome Business (2018-2023)
11.9.5 Aegerion Pharmaceuticals Recent Development
11.10 Akros Pharma
11.10.1 Akros Pharma Company Detail
11.10.2 Akros Pharma Business Overview
11.10.3 Akros Pharma Metabolic Syndrome Introduction
11.10.4 Akros Pharma Revenue in Metabolic Syndrome Business (2018-2023)
11.10.5 Akros Pharma Recent Development
11.11 Alnylam Pharmaceuticals
11.11.1 Alnylam Pharmaceuticals Company Detail
11.11.2 Alnylam Pharmaceuticals Business Overview
11.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Introduction
11.11.4 Alnylam Pharmaceuticals Revenue in Metabolic Syndrome Business (2018-2023)
11.11.5 Alnylam Pharmaceuticals Recent Development
11.12 Amarin
11.12.1 Amarin Company Detail
11.12.2 Amarin Business Overview
11.12.3 Amarin Metabolic Syndrome Introduction
11.12.4 Amarin Revenue in Metabolic Syndrome Business (2018-2023)
11.12.5 Amarin Recent Development
11.13 nAmgen
11.13.1 nAmgen Company Detail
11.13.2 nAmgen Business Overview
11.13.3 nAmgen Metabolic Syndrome Introduction
11.13.4 nAmgen Revenue in Metabolic Syndrome Business (2018-2023)
11.13.5 nAmgen Recent Development
11.14 Amicus Therapeutics
11.14.1 Amicus Therapeutics Company Detail
11.14.2 Amicus Therapeutics Business Overview
11.14.3 Amicus Therapeutics Metabolic Syndrome Introduction
11.14.4 Amicus Therapeutics Revenue in Metabolic Syndrome Business (2018-2023)
11.14.5 Amicus Therapeutics Recent Development
11.15 Arbutus Biopharma
11.15.1 Arbutus Biopharma Company Detail
11.15.2 Arbutus Biopharma Business Overview
11.15.3 Arbutus Biopharma Metabolic Syndrome Introduction
11.15.4 Arbutus Biopharma Revenue in Metabolic Syndrome Business (2018-2023)
11.15.5 Arbutus Biopharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma
*If Applicable.